I hate Alzheimer's. It's so insidious and there are very limited treatment options. That's why I was encouraged to learn of a promising treatment called Bryostatin. Developed by the Blanchette Rockefeller Neurosciences Institute (BRNI), the drug showed pre-clinical efficacy to not only treat Alzheimer's disease symptoms, but also its underlying causes.
Alzheimer's is the sixth leading cause of death in the United States. More than 5 million Americans have the disease, according to the Alzheimer's Association.
"We are very excited about the FDA's agreement for BRNI to move forward with clinical trials," said Dr. Daniel Alkon, Scientific Director of BRNI. "Bryostatin shows the promise to repair and protect against neurodegeneration caused by Alzheimer's disease, stroke and other brain trauma, as well as enhance the brain's normal memory functions."
Not only that, the drug has been shown to enhance and restore memory by rewiring connections in the brain previously destroyed by stroke, head trauma, or aging itself.
With Phase II permission granted, low doses will be tested on human Alzheimer's patients.
Here's hoping they're onto something big.
Comments